Biopharmaceutical companies are under mounting pressure to move faster, spend less, and ensure global compliance all without compromising innovation. This is especially true in clinical-stage manufacturing, where timelines and capital efficiency are everything.
In this new expert-authored article, BioCina explores why Australia is emerging as a global hub for biomanufacturing and how sponsors can benefit from its combination of tax rebates, regulatory efficiency, and advanced biopharma infrastructure.
Highlights include:
- Australia’s 48.5% tax incentive and how it substantially lowers clinical costs
- Regulatory pathways that eliminate IND requirements and reduce start-up time
- How BioCina’s Adelaide and Perth facilities enable seamless development for microbial, pDNA, LNP and mRNA programs, from drug substance through fill–finish
- The role of Australia’s national clinical trial network and digital health infrastructure in supporting faster, more efficient programs
With decades of operational excellence and Big Pharma heritage, BioCina is helping global clients turn Australia into a launchpad for clinical and commercial success.